Evidence map›Paper›PMID 34835481›Full record

ArticleMicroorganisms2021

Ceftazidime/Avibactam-Resistant

Carla Fontana, Marco Favaro, Laura Campogiani, Vincenzo Malagnino, Silvia Minelli, Maria Cristina Bossa, Anna Altieri, Massimo Andreoni, Loredana Sarmati

Open access · goldAbstract read
In one paragraph

Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Bacteriophage treatment is effective against carbapenem-resistantAntimicrobial agents and chemotherapy · 2025
    Article
  2. Article
  3. Screening ofAntibiotics (Basel, Switzerland) · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Resistance to Ceftazidime/Avibactam inAntibiotics (Basel, Switzerland) · 2023
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Carla FontanaDepartment of Experimental Medicine, "Tor Vergata" University, 00133 Rome, Italy.ORCID 0000-0003-2198-1947
Marco FavaroDepartment of Experimental Medicine, "Tor Vergata" University, 00133 Rome, Italy.
Laura CampogianiClinical Infectious Diseases, Department of System Medicine, "Tor Vergata" University, 00133 Rome, Italy.
Vincenzo MalagninoClinical Infectious Diseases, Department of System Medicine, "Tor Vergata" University, 00133 Rome, Italy.ORCID 0000-0002-6561-5298
Silvia MinelliLaboratory of Microbiology, Polyclinic of "Tor Vergata", 00133 Rome, Italy.
Maria Cristina BossaLaboratory of Microbiology, Polyclinic of "Tor Vergata", 00133 Rome, Italy.
Anna AltieriLaboratory of Microbiology, Polyclinic of "Tor Vergata", 00133 Rome, Italy.
Massimo AndreoniClinical Infectious Diseases, Department of System Medicine, "Tor Vergata" University, 00133 Rome, Italy.
Loredana SarmatiClinical Infectious Diseases, Department of System Medicine, "Tor Vergata" University, 00133 Rome, Italy.ORCID 0000-0003-1452-0333
University of Rome Tor Vergata · ITPoliclinico Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several

Indexed as

antibiotic resistancebeta-lactamase inhibitors resistanceceftazidime/avibactammulti-drug resistanceQ168L substitution

Identifiers

PMID34835481
PMCPMC8624296
OpenAlexW3213543470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.